SHANDONG WEIGAO ORTHOPAEDIC DEVICE CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.98 CNY | +1.73% |
|
+5.56% | -34.91% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 60% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company returns high margins, thereby supporting business profitability.
Weaknesses
- With an expected P/E ratio at 43.52 and 32.9 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -34.91% | 1.49B | - | ||
| +73.43% | 12.41B | B- | ||
| -16.51% | 8.14B | C+ | ||
| +16.03% | 7.2B | C- | ||
| +3.66% | 5.93B | B | ||
| +13.07% | 5.43B | D+ | ||
| +36.46% | 4.89B | - | ||
| -19.82% | 4.09B | B- | ||
| -34.06% | 2.49B | C | ||
| 0.00% | 2.04B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 688161 Stock
- Ratings Shandong Weigao Orthopaedic Device Co., Ltd